scholarly journals Lymphocyte to Monocyte Ratio and C-Reactive Protein Combination as the Best Simple Predictor of Treatment Response in Cirrhotic Patients With Culture Negative Neutrocytic Ascites

2021 ◽  
Author(s):  
Sezgin Barutcu
Keyword(s):  
Treatment Response ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Lymphocyte To Monocyte Ratio ◽  
Cirrhotic Patients ◽  
Culture Negative

C reactive protein contributes to the early prediction of 90-day mortality risk in acutely decompensated cirrhotic patients

2017 ◽  
Vol 66 (1) ◽  
pp. S126-S127
Author(s):  
A. Clemente ◽  
M. Romero ◽  
C. Martínez ◽  
A. Bueno ◽  
M. Antona ◽  
...  
Keyword(s):  
Mortality Risk ◽  
Early Prediction ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Cirrhotic Patients

C-reactive protein as a specific marker of infection in cirrhotic patients

2010 ◽  
Vol 30 (3) ◽  
pp. 487-488
Author(s):  
Aristotelis Tsiakalos ◽  
Aggelos Karatzaferis ◽  
Panayiotis Ziakas ◽  
Gregorios Hatzis
Keyword(s):  
Specific Marker ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Cirrhotic Patients

Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites

2019 ◽  
Vol 37 (3) ◽  
pp. 239-246 ◽  
Author(s):  
Yohei Kida
Keyword(s):  
Therapeutic Response ◽  
Positive Response ◽  
Body Weight Loss ◽  
Newly Diagnosed ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
V2 Receptor ◽  
Vasopressin V2 Receptor Antagonist ◽  
Cirrhotic Patients

Aims: Ascites is one of the major complications in advanced cirrhotic patients. Tolvaptan is a non-peptide orally available arginine vasopressin V2 receptor antagonist. We investigated and found that tolvaptan therapy improved the prognosis and predictive factor of cirrhotic patients with ascites. Methods: Overall, 99 patients with newly diagnosed ascites with cirrhosis were enrolled. No patients had intrahepatic malignancy. The patients were divided into 2 groups based on tolvaptan therapy: 86 patients treated with tolvaptan (tolvaptan-group) and 13 patients treated without tolvaptan (non-tolvaptan-group). Tolvaptan-responder was defined as body weight loss of ≥1.5 kg/week after administering tolvaptan. Results: Tolvaptan therapy was effective in 61.6% of cirrhotic patients. There was a significant difference in the overall survival (OS) between the tolvaptan-responder-group and the other groups (p < 0.001). Male (HR 5.05; p = 0.01), tolvaptan responder (HR 0.21; p = 0.02), and dosage of furosemide < 40 mg/day (HR 0.17; p = 0.01) were factors that were independently associated with the OS. The multivariate analysis revealed that C-reactive protein < 0.9 mg/dL (HR 0.07; p = 0.001), and furosemide dosage < 40 mg/day (HR 0.09; p = 0.003) were independently associated with the tolvaptan response. Conclusion: Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites. These preliminary findings warrant validation and further exploration.

The Kidney, Liver, Index surgery and C reactive protein score is a predictor of treatment response in acute prosthetic joint infection

2017 ◽  
Vol 42 (1) ◽  
pp. 33-38 ◽  
Author(s):  
C Jiménez-Garrido ◽  
J M Gómez-Palomo ◽  
I Rodriguez-Delourme ◽  
F J Durán-Garrido ◽  
E Nuño-Álvarez ◽  
...  
Keyword(s):  
Treatment Response ◽  
Prosthetic Joint Infection ◽  
Joint Infection ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Liver Index ◽  
Prosthetic Joint ◽  
Kidney Liver
Sign in / Sign up

Export Citation Format

Share Document